JP2009538824A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538824A5
JP2009538824A5 JP2009502755A JP2009502755A JP2009538824A5 JP 2009538824 A5 JP2009538824 A5 JP 2009538824A5 JP 2009502755 A JP2009502755 A JP 2009502755A JP 2009502755 A JP2009502755 A JP 2009502755A JP 2009538824 A5 JP2009538824 A5 JP 2009538824A5
Authority
JP
Japan
Prior art keywords
amylin
pharmaceutical composition
disorder
composition according
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009502755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538824A (ja
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed filed Critical
Priority claimed from PCT/US2006/038919 external-priority patent/WO2007114838A1/en
Publication of JP2009538824A publication Critical patent/JP2009538824A/ja
Publication of JP2009538824A5 publication Critical patent/JP2009538824A5/ja
Pending legal-status Critical Current

Links

JP2009502755A 2006-03-31 2006-10-04 精神疾患及び障害治療用アミリン及びアミリンアゴニスト Pending JP2009538824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (2)

Publication Number Publication Date
JP2009538824A JP2009538824A (ja) 2009-11-12
JP2009538824A5 true JP2009538824A5 (cg-RX-API-DMAC7.html) 2009-12-24

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009502755A Pending JP2009538824A (ja) 2006-03-31 2006-10-04 精神疾患及び障害治療用アミリン及びアミリンアゴニスト

Country Status (7)

Country Link
EP (1) EP2010208A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009538824A (cg-RX-API-DMAC7.html)
KR (1) KR20080106950A (cg-RX-API-DMAC7.html)
AU (1) AU2006341375B2 (cg-RX-API-DMAC7.html)
CA (1) CA2647568A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012666A (cg-RX-API-DMAC7.html)
WO (1) WO2007114838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー/エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2013511287A (ja) 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법

Similar Documents

Publication Publication Date Title
Fox et al. Levodopa‐related motor complications—Phenomenology
JP2007508236A (ja) うつ病およびその他の情動障害を治療する方法
RU2011124515A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил) бензо[b] тиофен-2-карбоксамидом и его фармацевтически приемлемыми солями
JP2007516193A5 (cg-RX-API-DMAC7.html)
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
Li et al. The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia
JP2011515391A5 (cg-RX-API-DMAC7.html)
MX2010009403A (es) Derivados de 2-aminoquinolina.
Catapano-Friedman Effectiveness of quetiapine in the management of psychotic depression in an adolescent boy with bipolar disorder, mixed, with psychosis
Yumatov Emotional stress: the dialectics of nature
WO2010026110A3 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
Prater et al. Johanson-Blizzard syndrome—a case study, behavioral manifestations, and successful treatment strategies
MX2010009820A (es) 2-aminoquinolinas como antagonistas del receptor 5-hidroxitriptamina 5a.
Lee Anti-platelet effects of artemisinin through regulation of cyclic nucleotide on collagen-induced human platelets
Subhash et al. Alterations in 5-HT1A receptors and adenylyl cyclase response by trazodone in regions of rat brain
Salzman Treat the Patient, Not the Rule Book…: The Art of Psychopharmacology!
Yang et al. Perioperative Nursing Experience with a Patient with Ketamine Cystitis.
Thakur et al. Dark Side of Cannabis: Impact on Mental Health and Rising Abuse
Keeler The Status of Psychedelic Microdosing: What We Know Now and What We Need to Find Out.
Sararoodi et al. The Relationship of History of Hypertension and Illness Cognitive Representation in Post-Myocardial Infarction.
Martin et al. Psychiatric treatments: an exciting new century
Byarugaba The Response of the Roman Catholic Church in South Africa to the Problems of HIV/AIDS In Light of the Modern Catholic Social Teaching.
McKenna BUT WHAT IF THE “FIELD” IS A MOTHER–BABY BEHAVIOURAL SLEEP LABORATORY?
Najavits The Case of Jared.
Coughlan et al. Crystal Methamphetamine-ICE